Mr. Hugh MacNaught reports

DUKE UNIVERSITY HEALTH CENTER -- ONE OF AMERICA'S TOP HEART-CARE INSTITUTIONS AND INNOVATORS -- PURCHASES VENTRIPOINT'S AI HEART-SCAN TECHNOLOGY

Duke University Health Center has purchased its second VMS+ unit from Ventripoint Diagnostics Ltd., which processes ultrasound images of the heart to generate MRI-quality measurements in minutes.

Duke Health Center Arringdon, part of the Duke University Health System located in Durham, N.C., Duke Health is affiliated with Duke University and is a world-class academic and health care system.

"Tools that allow us to reduce the cost and time needed for reliable diagnostics can potentially save the lives of infants, children and adults with heart conditions," said Richard Krasuski, MD, director of Duke's Adult Congenital Heart Program.

Duke Children's Hospital has been using Ventripoint's VMS+ system for two years, focusing primarily on single ventricle paediatric patients. Now, the VMS+ will be implemented at Duke Cardiology Arringdon and will be used in real-time adult patient heart scans and help Duke further its study of Ventripoint's potential.

"We are very excited to work with Duke Cardiology Arringdon on our latest VMS+ system for their cardiac clinic," said Ventripoint interim chief executive officer Hugh MacNaught. "We have had great success working with Duke for their children's health clinic, and we are sure that the adult congenital heart disease program will also experience great results."

The VMS+ provides diagnostic and treatment procedures, resulting in scans of all four chambers of the heart at a fraction of the cost and time needed for cardiac MRIs. The ease of use of Ventripoint's artificial intelligence technology also means that patients can receive numerous heart scans, to assist caregivers in treatment and patient monitoring.

As part of the purchase order, Ventripoint will update its software at Duke as the VMS+ advances its capabilities. Ventripoint's VMS+ is now being used in hospitals in the United States, Europe, the United Kingdom and Canada.

Corporate update

In addition to the aforementioned sale, over the past month the company has completed and filed its audited financial statements, initiated an off-the-market financing, hosted meetings with its European distributor, prepared for the AEPC conference, refreshed its website and continued the development of VMS+ 4.0.

Conference call details

The company will hold a conference call to discuss this progress.

• Monday, May 6, 2024, at 4 p.m. Eastern Time.

Dial-in details will display on screen, and a calendar invitation will be sent by e-mail. Registration will remain open through to the end of the call.

Participants who prefer to speak with an operator may dial 1-844-763-8274 or 1-647-484-8814. It is recommended that you call 10 minutes before the scheduled start time to avoid the queue.

After the call, an audio recording will be made available via telephone for one month, until end of day June 3. The recording can be accessed by dialling 1-855-669-9658 or 1-604-674-8052 and using the access code 0892 followed by the pound key.

A written transcript of the call will be available on Ventripoint's website shortly after its conclusion.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.